Benoit-Lizon Isis, Apetoh Lionel
INSERM, U1231, Dijon, France; Faculté de Médecine, Université de Bourgogne Franche Comté, Dijon, France.
INSERM, U1231, Dijon, France; Faculté de Médecine, Université de Bourgogne Franche Comté, Dijon, France; Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
Semin Immunol. 2021 Feb;52:101477. doi: 10.1016/j.smim.2021.101477. Epub 2021 Apr 21.
CD4 T cell effector subsets not only profoundly affect cancer progression, but recent evidence also underscores their critical contribution to the anticancer efficacy of immune checkpoint inhibitors. In 2012, the two seminal studies suggested the superior antimelanoma activity of T9 cells over other T cell subsets upon adoptive T cell transfer. While these findings provided great impetus to investigate further the unique functions of T9 cells and explore their relevance in cancer immunotherapy, the following questions still remain outstanding: are T9 cell anticancer functions restricted to melanoma? What are the factors favouring T9 cell effector functions? What is the contribution of T9 cells to cancer immunotherapy treatments? Can T9 cells be identified in humans and, if so, what is their clinical relevance? By reviewing the studies addressing these questions, we will discuss how T9 cells could be therapeutically harnessed for cancer immunotherapy strategies.
CD4 T细胞效应子亚群不仅深刻影响癌症进展，而且最近的证据还强调了它们对免疫检查点抑制剂抗癌疗效的关键贡献。2012年，两项开创性研究表明，在过继性T细胞转移后，T9细胞对黑色素瘤的抗癌活性优于其他T细胞亚群。虽然这些发现为进一步研究T9细胞的独特功能及其在癌症免疫治疗中的相关性提供了巨大动力，但以下问题仍然悬而未决：T9细胞的抗癌功能是否仅限于黑色素瘤？哪些因素有利于T9细胞的效应子功能？T9细胞对癌症免疫治疗有何贡献？能否在人类中识别出T9细胞？如果可以，它们的临床相关性是什么？通过回顾针对这些问题的研究，我们将讨论如何将T9细胞用于癌症免疫治疗策略。
